Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Declines By 66.6%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 201,697 shares, a decline of 66.6% from the December 31st total of 603,238 shares. Based on an average daily volume of 454,313 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the shares of the company are sold short. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 454,313 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wall Street Zen upgraded Enlivex Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Enlivex Therapeutics in a research note on Monday, December 29th. HC Wainwright boosted their price target on Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 12th. D. Boral Capital reissued a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday, November 24th. Finally, D Boral Capital downgraded shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enlivex Therapeutics currently has an average rating of “Hold” and a consensus price target of $13.00.

Institutional Trading of Enlivex Therapeutics

A number of hedge funds have recently made changes to their positions in ENLV. Susquehanna International Group LLP purchased a new stake in Enlivex Therapeutics in the 3rd quarter worth approximately $57,000. Jane Street Group LLC lifted its holdings in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares during the last quarter. Finally, Citizens Financial Group Inc. RI acquired a new position in Enlivex Therapeutics in the 3rd quarter valued at $241,000. 1.02% of the stock is owned by hedge funds and other institutional investors.

Enlivex Therapeutics Stock Down 2.9%

Enlivex Therapeutics stock traded down $0.03 during mid-day trading on Friday, hitting $1.01. 350,705 shares of the company’s stock traded hands, compared to its average volume of 478,084. Enlivex Therapeutics has a one year low of $0.66 and a one year high of $2.10. The firm has a 50 day moving average price of $0.92 and a 200 day moving average price of $1.07. The company has a market cap of $239.75 million, a PE ratio of -1.84 and a beta of 1.52.

Enlivex Therapeutics (NASDAQ:ENLV) last released its earnings results on Friday, November 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. On average, analysts expect that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.